We also show that targeting B-cell-mediated immunosuppression in HCC can prevent the acquired resistance to ICB and STING agonist therapy in murine HCC and identify the immune checkpoint TIM-1 as a novel target for HCC treatment (Fig. 7). Here, STING1 is linked to hepatocellular carcinoma.